Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Merck
Merck
SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal
Yahoo/Benzinga
Wed, 06/22/22 - 10:50 am
Merck
Seagen
M&A
Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome
BioSpace
Wed, 06/22/22 - 10:26 am
Medtech
diagnostics
Illumina
Myriad Genetics
TruSight Oncology 500
cancer
Merck
BMS, Pfizer and Merck face steep patent cliffs but all have the financial flexibility for M&A: Moody's
Fierce Pharma
Tue, 06/21/22 - 11:56 pm
Pfizer
Merck
Bristol Myers Squibb
patents
patent cliffs
M&A
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development
BioSpace
Tue, 06/21/22 - 12:02 pm
Merck
Emergent BioSolutions
Affinivax
Ocugen
vaccines
chikungunya virus
pneumococcal disease
COVID-19
Merck and Agilent to advance process analytical technologies for downstream processing
Biopharma Reporter
Tue, 06/21/22 - 11:00 am
Merck
Agilent
process analytical technologies
drug manufacturing
Report: Merck Looks into Possible Buyout of Seagen
BioSpace
Mon, 06/20/22 - 10:38 am
Merck
Seagen
M&A
Merck Predicts Over 80 Potential Oncology Approvals Through 2028
BioSpace
Wed, 06/8/22 - 10:32 am
Merck
oncology
ASCO 2022
Keytruda
#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets
Endpoints
Mon, 06/6/22 - 10:31 am
ASCO 2022
CG Oncology
Merck
Keytruda
EQRx
sugemalimab
Yumanity's end: J&J pays $26M for neuroscience assets as reverse merger erases biotech
Fierce Biotech
Mon, 06/6/22 - 10:29 am
Yumanity Therapeutics
JNJ
Kineta
Merck
M&A
ASCO: Merck touts Keytruda's 'convergent' benefits across postsurgery lung cancer patient groups
Fierce Pharma
Mon, 05/30/22 - 10:18 am
ASCO 2022
Merck
Keytruda
lung cancer
ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options
Fierce Biotech
Fri, 05/27/22 - 10:17 am
ASCO 2022
Merck
Keytuda
Lynparza
Lenvima
Merck study results signal blood cancer potential for new type of immunotherapy
BioPharma Dive
Thu, 05/26/22 - 10:40 pm
Merck
Bristol Myers Squibb
cancer
cancer immunotherapy
favezelimab
Hodgkin's lymphoma
US sees spike in Paxlovid usage as Merck's molnupiravir and AstraZeneca's Evusheld are slower off the shelf
Endpoints
Wed, 05/25/22 - 11:47 pm
Pfizer
HHS
Paxlovid
Merck
molnupiravir
AstraZeneca
Evusheld
COVID-19
The patent winter is coming
EP Vantage
Wed, 05/25/22 - 10:41 am
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
Merck snaps up cancer drug from China’s Kelun in $1.4bn deal
Pharmaforum
Wed, 05/18/22 - 11:53 pm
Merck
immuno-oncology
China
Sichuan Kelun Pharmaceutical
Pfizer, Merck, AstraZeneca led Big Pharma's growth in Q1 but they couldn't match mRNA hotshots
Fierce Pharma
Tue, 05/17/22 - 10:43 am
Big Pharma
earnings
Pfizer
Merck
AstraZeneca
COVID-19
Moderna Therapeutics
BioNTech
Big pharma’s biggest spenders revealed
EP Vantage
Tue, 05/17/22 - 10:29 am
R&D
licensing
M&A
COVID-19
Big Pharma
Bristol Myers Squibb
JNJ
AbbVie
Sanofi
Merck
Novartis
Pfizer
AstraZeneca
Roche
GSK
Eli Lilly
ICER says Pfizer's Paxlovid, Merck's molnupiravir both cost effective, but their benefits are far from equal
Fierce Pharma
Tue, 05/10/22 - 10:50 am
ICER
Pfizer
Paxlovid
Merck
Ridgeback Biotherapeutics
molnupiravir
COVID-19
In wake of Biogen's skirmish with the SEC, pharma giants are changing the way they do quarterly reports
Endpoints
Thu, 05/5/22 - 11:34 pm
Biogen
earnings
SEC
Eli Lilly
Merck
Bristol Myers Squibb
Pfizer
AbbVie
Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1
Pharmaforum
Thu, 04/28/22 - 10:48 pm
Merck
earnings
COVID-19
Lagevrio
Pages
« first
‹ previous
…
13
14
15
16
17
18
19
20
21
…
next ›
last »